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SUMMARY. Hepatitis C virus (HCV) infection is closely associated with lipid metabolism 
defects throughout the viral lifecycle, with hepatic steatosis frequently observed in patients 
with chronic HCV infection. Hepatic steatosis is most common in patients infected with 
genotype 3 viruses, possibly due to direct effects of genotype 3 viral proteins. Hepatic 
steatosis in patients infected with other genotypes is thought to be mostly due to changes in 
host metabolism, involving insulin resistance in particular. Specific effects of the HCV 
genotype 3 core protein have been observed in cellular models in vitro: mechanisms linked to 
a decrease in microsomal triglyceride transfer protein activity, decreases in the levels of 
peroxisome proliferator-activating receptors, increases in the levels of sterol regulatory 
element-binding proteins, and phosphatase and tensin homologue downregulation. Functional 
differences between the core proteins of genotype 3 viruses and viruses of other genotypes 
may reflect differences in amino-acid sequences. However, bioclinical studies have failed to 
identify specific “steatogenic” sequences in HCV isolates from patients with hepatic steatosis. 
It is therefore difficult to distinguish between viral and metabolic steatosis unambiguously 
and host and viral factors are probably involved in both HCV genotype 3 and non-3 steatosis. 
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INTRODUCTION 
Hepatic steatosis, defined as excessive lipid accumulation in the cytoplasm of hepatocytes, is 
a frequent histological feature in patients chronically infected with hepatitis C virus (HCV) 
(Figure 1). Before the identification and characterisation of HCV in 1989, the presence of 
steatosis was used to discriminate between so-called “non-A non-B” hepatitis and other forms 
of chronic liver disease, such as hepatitis B or autoimmune hepatitis. This suggests a probable 
direct role for HCV in the development of excess fat accumulation in the liver. However, the 
mechanisms underlying hepatic steatosis in HCV-infected patients are difficult to unravel, due 
to the possible co-existence of several confounding factors, including metabolic syndrome, 
type 2 diabetes, obesity and a high body mass index (BMI), in patients. These cofactors may 
occur together in HCV patients and may cause various degrees of hepatic steatosis through 
mechanisms similar to those of classical non-alcoholic fatty liver disease (NAFLD), mostly 
through insulin resistance [1, 2]. Furthermore, hepatic steatosis may result from other 
challenges to the liver, particularly in cases of excessive alcohol consumption. 
It has been suggested that there are two main types of steatosis in patients with hepatitis 
C. The first is a metabolic type of steatosis associated with a high BMI, hyperlipidaemia and 
insulin resistance. The second is a virally induced form of steatosis that develops in the 
absence of other “steatogenic” cofactors and that seems to be directly triggered by the virus. 
The situation is further complicated by the possible role of HCV as a cofactor in the 
development of the metabolic type of steatosis, this virus has itself been shown to induce 
insulin resistance, potentially favouring the development of hepatic steatosis [3, 4]. 
Nevertheless, virally induced steatosis is widely considered to be predominantly, and perhaps 
strictly, linked to HCV genotype 3 infection [5]. The HCV RNA genome displays 
considerable diversity, both within and between isolates, and three levels of classification 
have been adopted, grouping viral sequences into six genotypes, several dozen subtypes and 
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intra-isolate variants. Hepatic steatosis is common in patients infected with genotype 3 viruses 
and seems to be directly related to intrahepatic viral load, suggesting a direct viral effect that 
is not observed with other genotypes [6]. Moreover, following successful HCV eradication by 
antiviral therapy, hepatic steatosis resolves in most individuals infected with genotype 3 
viruses, but not in those infected with genotype 1 viruses [7]. Further evidence supporting this 
link has been provided by in vitro studies showing that the HCV core protein induces lipid 
droplet (LD) accumulation that is more pronounced with genotype 3 proteins than with 
proteins from viruses of other genotypes [8-10]. In this review, I discuss the basic and clinical 
aspects of this link between HCV diversity, including genotype classification, and steatosis 
development. 
 
MOLECULAR MECHANISMS OF HCV-INDUCED STEATOSIS 
The close association of HCV with steatosis should probably be analysed in the light of 
evidence from many basic studies demonstrating that the virus hijacks the lipid-producing 
machinery of the hepatocyte for its own benefit. In cell culture, the HCV core protein 
associates with lipid droplets (LD) [11], inducing the clustering and accumulation of these 
lipid storage organelles [12, 13]. This LD clustering and accumulation might be the 
consequence of a decrease in LD turnover induced by the interaction of the HCVcore protein 
with a host cell enzyme that synthesizes triglycerides in the ER, the diacylglycerol 
acyltransferase 1 (DGAT1) [14, 15]. HCV virions are then formed at endoplasmic reticulum 
(ER) membranes directly apposed to these clustered LD [16, 17], suggesting that virus-
induced steatosis may be a consequence of viral lifecycle strategy [18]. HCV particles are 
then secreted and circulate as very low-density lipoprotein (VLDL)-virus complexes rich in 
triglycerides [19]. These particles, which are known as lipoviro particles (LVPs), contain viral 
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RNA, viral structural proteins (core and envelope E1 and E2 proteins) and the host-derived 
apolipoproteins B and E (apoB and apoE) [19]. 
Specific mechanisms have been proposed to account for virally induced steatosis. These 
mechanisms involve decreases in the levels of microsomal triglyceride transfer protein 
(MTP), and peroxisome proliferator-activating receptors (PPARs), increases in sterol 
regulatory element binding protein (SREBP) levels, oxidative stress due to the production of 
reactive oxygen species (ROS) and phosphatase and tensin homologue (PTEN) 
downregulation (Figure 2). 
 
MTP 
MTP, which is present in the ER lumen, stabilises apoB by lipidation. Lipidated apoB binds 
triglycerides, forming VLDL for export from hepatocytes. HCV core [20] and non-structural 
proteins [21] have been shown to decrease the activity of MTP, resulting in the accumulation 
of intracellular lipids due to a decrease in VLDL export. Several studies have reported low 
serum triglyceride concentrations in patients chronically infected with HCV [22]. In human 
liver biopsy specimens, MTP mRNA levels are inversely correlated with the degree of hepatic 
steatosis, regardless of HCV genotype [23]. However, patients infected with genotype 3 
viruses have significantly lower levels of MTP activity than patients infected with other 




The PPAR nuclear receptors belong to the steroid superfamily. PPAR is strongly expressed 
in hepatocytes, in which it regulates lipid metabolism through fatty acid import into 
mitochondria and the activation of oxidative enzymes. Decreases in PPARactivity probably 
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cause fatty acid uptake and a decrease in mitochondrial oxidation, resulting in hepatic 
steatosis. Liver biopsy specimens from patients with chronic HCV infection have been shown 
to contain lower levels of PPARand its target gene transcripts than specimens from controls 
[24]. More detailed analyses have shown that PPAR mRNA levels are even lower in patients 
infected with genotype 3 viruses than in those infected with genotype 1 viruses [25], 
suggesting that this inhibition may also involve genotype-dependent mechanisms. 
 
SREBPs 
SREBPs constitute a family of ER membrane-associated transcription factors that regulate the 
production of enzymes involved in lipogenesis. The SREBP-1c isoform is produced 
predominantly in the liver. In its inactivated form, it binds the SREBP cleavage-activating 
protein (SCAP). Low intracellular sterol concentrations lead to cleavage from SCAP, the 
resulting SREBP being translocated to the nucleus (nuclear SREBP; nSREBP), where it binds 
to the SREBP response element (SRE), up-regulating the transcription of genes involved in 
lipogenesis. Various methods accounting for the increase in lipogenesis due to SRBP 
activation by HCV have been described in cellular models in vitro. SREBP mRNA levels 
increase in cells producing the HCV core protein, resulting in an increase in fatty acid 
synthesis within hepatocytes [26]. It was shown in an in vitro study that fatty acid synthetase 
(FAS) was more strongly induced, in an SRBP1c-dependent manner, by genotype 3 core 
proteins than by genotype 1 core proteins [27]. However, these results were called into 
question by a study reporting a lack of specific increase in the expression of genes involved in 
lipogenesis following SREBP activation in the livers of patients infected with genotype 3 
viruses [28]. HCV-induced oxidative stress and the subsequent activation of the 
phosphatidylinositol 3-kinase (PI3-K)-Akt pathway and PTEN inactivation have also been 
shown to mediate the transactivation of SREBPs [29]. Again, this phenomenon was found to 
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be more marked with genotype 3 core protein than with genotype 1 core protein. Finally, the 




HCV core protein directly increases the level of ROS products by inhibiting electron transport 
and modifying mitochondrial permeability [31, 32]. This ROS production leads to the 
peroxidation of membrane lipids and proteins involved in trafficking and secretion, inhibiting 
VLDL secretion. In addition to the direct effects of HCV proteins on the mitochondria, HCV-
induced immune activation may also cause oxidative stress through cytokine release and 
macrophage activation. Moreover, the release of proinflammatory cytokines, such as tumour 
necrosis factor  (TNF), further promotes insulin resistance, which may in turn favour the 
development of hepatic steatosis. 
 
PTEN 
A new mechanism specifically attributable to the HCV core protein of genotype 3 isolates has 
recently been proposed [33]. PTEN, the intrahepatic downregulation of which has been shown 
to contribute to the development of steatosis in NAFLD, has been shown to be downregulated 
by a genotype 3 core protein in cellular models in vitro, via a mechanism involving a 
microRNA-dependent blockade of PTEN mRNA translation. By contrast, no such effect is 
observed with genotype 1 core protein. 
 
HCV AND INSULIN RESISTANCE 
Like metabolic syndrome, chronic HCV infection is associated with insulin resistance [34]. 
Glucose metabolism is modified to a significantly greater extent in the early stages of chronic 
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HCV infection than in chronic hepatitis B virus (HBV) infection. HCV infection thus causes 
insulin resistance, which can progress to type 2 diabetes mellitus in susceptible individuals 
[35]. Various mechanisms have been put forward to account for the induction of insulin 
resistance by HCV. Direct effects in hepatocytes have been attributed to viral interference 
with the insulin signal transduction pathway mediated by HCV core protein and to the ER 
stress induced by viral replication (reviewed in [36]). However, insulin resistance has also 
been shown to occur in uninfected cells, such as striated muscle cells, by unknown 
mechanisms [3]. Interestingly, the adipose tissue did not appear to be involved in the 
pathogenesis of viral insulin resistance, as free fatty acid efflux from adipose tissue responds 
to insulin in normal persons and in patients with chronic hepatitis C [3]. Liver tissues contain 
large numbers of insulin receptors. The liver controls hepatic glucose production, the 
replenishment of glycogen stores, increases in triglyceride biosynthesis and decreases in 
VLDL and apoB production and secretion. In conditions of insulin resistance, hepatic 
steatosis has been shown to occur principally due to an increase in the influx of fatty acids 
into the liver, as a result of higher levels of peripheral lipolysis and hepatic lipogenesis [37]. 
Decreases in fatty acid oxidation and fat export further contribute to hepatic steatosis [38]. 
Furthermore, hyperinsulinaemia leads to the direct activation of SREBP-1c, causing 
lipogenesis [38]. Patients with chronic HCV infection have significantly higher fasting serum 
insulin concentrations and homeostatic model assessments (HOMAR-IR, a marker for insulin 
resistance) than healthy volunteers [39, 40]. Moreover, patients infected with a genotype 3 
virus have significantly lower HOMA-IR values than patients infected with other genotypes, 
providing support for the widely held view that hepatic steatosis is virally induced in 
genotype 3 infections but metabolically induced in infections with other genotypes [39, 40]. 
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HCV SEQUENCES INVOLVED IN STEATOSIS 
Studies in early experimental in vitro expression systems and transgenic mouse models 
showed that the HCV core protein was sufficient to induce triglyceride accumulation in 
hepatocytes [20, 41, 42]. All these early reports were based on studies using constructs 
derived from a genotype 1 genome. More recent investigations have been conducted with in 
vitro cellular models expressing the HCV genotype 3 core protein that has been found to 
result in higher levels of triglyceride accumulation than the genotype 1 core protein [8]. These 
functional differences between genotype 1 and 3 core proteins may result from differences in 
their amino-acid sequences, although these sequences are very similar. The search for viral 
sequences responsible for genotype 3 core protein-specific effects on triglyceride 
accumulation led to the identification of a single amino-acid change, at position 164 [9]. A 
phenylalanine (F) residue in this position, as found in genotype 3 core sequences, has been 
shown to be specifically associated with higher levels of lipid droplet accumulation in cellular 
models in vitro. In almost all the core sequences of viruses of other genotypes, this residue is 
replaced by a tyrosine (Y) [9]. Similarly, higher levels of lipid droplet accumulation were 
observed in a study in which an HCV core protein sequence from a genotype 3 virus was 
produced in a cellular model [8]. However, the authors were unable to identify the residues 
involved in this phenomenon, and did not implicate F164. Nevertheless, this particular residue 
was directly implicated in the stronger FAS activation observed with the genotype 3 core 
protein [27]. Another study reporting the sequencing of the core gene from genotype 3 viruses 
infecting patients with or without steatosis led to the identification of two additional residues 
correlated with lipid accumulation: phenylalanine-valine (FV) or leucine-isoleucine (LI) at 
positions 182 and 186 (as opposed to FI) [10]. The production in vitro of core proteins with 
these FV or LI residues resulted in significantly higher intracellular lipid levels than the 
production of core proteins with FI residues in these positions. However, in two other 
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independent studies, analyses of the sequences of various clinical isolates failed to implicate 
the FV and LI residues in positions 182 and 186, or any other genetic differences between 
genotype 3 core proteins from patients with and without steatosis, suggesting a possible role 
for other factors in the development of steatosis in patients infected with genotype 3 viruses 
[43, 44]. In all these bioclinical studies, it was difficult to evaluate the role of the F164 residue 
in liver steatosis, because this residue was present in all genotype 3 isolates, even those from 
patients without steatosis [10, 43, 44] (Figure 3). Nevertheless, an F residue was never 
detected in position 164 in any of the genotype 1 strains associated with severe steatosis [44]. 
Overall, studies using in vitro cellular models to compare the intracellular lipid accumulation 
induced by genotype 3 and genotype 1 core proteins have not generated consistent results [8-
10, 27, 43] (Figure 3).  These differences may be due to the different cell models and lipid 
droplet quantification methods used in these studies. One might assume that human liver cell 
lines would constitute the best model, but Huh7 cells have been reported to have intracellular 
lipid levels in standard culture conditions too high for the detection of meaningful differences 
between the proteins studied [10]. This was confirmed with the HCV in cell culture (HCVcc) 
model, as viruses bearing structural proteins (the core and envelope E1 and E2 proteins) from 
a genotype 2 or a genotype 3 strain induced the accumulation of similar numbers of lipid 
droplets when propagated in Huh7 cells [45]. Furthermore, despite a polymorphism between 
the genotype 2 strains J6 and JFH1 at residue 164 (Y in JFH-1, F in J6), the propagation of 
JFH-1 and J6/JFH-1 HCVcc in Huh7 cells did not result in any significant differences in lipid 
droplet amount (unpublished personal observation). However, one study comparing these two 
viruses has shown that a virus bearing the J6 core sequence is more efficiently assembled and 
secreted from infected cells, but has lower ability to induce the LD clustering [46]. This 
suggests that the viral assembly efficiency by itself might influence the lipid storage, through 
the core protein dependent use of the LD as viral assembly platform. Thus, even if the core 
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protein is central in this process, the effect of the HCV infection on the cellular lipid load 
might also depend on the interaction between this protein and other viral partners involved in 
virion assembly. Interestingly, the binding of the core protein to the non-structural NS5A 
protein is critical for virus particle assembly [47], and this protein has been shown to also 
interact with lipid metabolism [48], inducing steatosis in a transgenic mouse model [49]. As a 
result, one bioclinical study also analysed the NS5A sequences of the viral variants circulating 
in patients with and without steatosis [44]. No differences in the sequence of the NS5A gene 
were found between patients with and without steatosis, suggesting that other viral proteins 
and, probably, host factors are involved in the development of steatosis in genotype 3 
infection. However, although recent data have suggested that the polymorphism of various 
host genes, including the PPAR, IL-28B, adiponutrin and MTP genes, may influence the 
development of more severe steatosis in chronic carriers of HCV, this phenomenon seems to 
concern principally patients infected with non-genotype 3 viruses [50-56]. 
 
OTHER POTENTIAL LINKS BETWEEN HCV GENOTYPE 3 AND HEPATIC 
STEATOSIS 
In Western Europe, genotype 3 infection is more frequent in patients with a history of 
intravenous drug use (IVDU) than in non-drug users [57]. Moreover, alcohol abuse has been 
reported to be particularly frequent in patients with a history of IVDU [58, 59]. Therefore, 
although this relationship is certainly not strict and remains speculative, these observations 
suggest that alcohol consumption may be associated with a HCV genotype 3 infection, at least 
in some patients. This is of potential importance, as ethanol metabolism also causes 
mitochondrial injury and is thought to act in synergy with HCV to produce ROS [60]. 
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CONCLUSION 
Several studies have shown an association between steatosis and the progression of liver 
fibrosis and advanced liver disease in chronic hepatitis [61]. Virally induced steatosis does not 
seem to be associated with advanced stages of fibrosis and the association described in 
previous reports may essentially be due to metabolic steatosis [62]. However, the failure to 
identify unambiguously specific “steatogenic” sequences in genotype 3 isolates from patients 
with hepatic steatosis suggests that there is no clear dichotomy between virally induced and 
metabolically induced hepatic steatosis. The overlap between the two forms of steatosis in 
chronic carrier of HCV may be greater than previously thought and further studies are clearly 
required to improve our understanding of the relationship and molecular interactions between 
these two forms. 
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Fig. 1 Electron micrographs showing the accumulation of large lipid droplets (LD) in the 
cytoplasm of hepatocytes on liver biopsy specimens from four chronic HCV carriers. (nuc = 
nucleus). Scale bars: 5 m in A, 2 m in B, C and D. 
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Fig. 2 Schematic diagram of the principal mechanisms put forward to account for lipid 
accumulation in HCV-infected hepatocytes. HCV interferes with the production and/or 
activity of microsomal triglyceride transfer protein (MTP), a luminal ER protein involved in 
very low-density lipoprotein (VLDL) assembly and export. HCV inhibits transcription of the 
gene encoding peroxisome proliferator activating receptor  (PPAR, a nuclear factor 
downregulating the synthesis of enzymes involved in fatty acid -oxidation, such as carnitine 
palmitoyltransferase I. HCV activates sterol regulatory element binding protein 1c (SREBP-
1c), a nuclear transcription factor controlling the expression of genes encoding enzymes 
involved in fatty acid synthesis. HCV leads to the production of reactive oxygen species 
(ROS), which induce the peroxidation of membrane lipids and proteins involved in trafficking 
and secretion, inhibiting VLDL secretion. Mechanisms associated with the inhibition of MTP 
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and PPAR and the activation of SREBP-1c have been shown to be more pronounced in 
cases of infection with genotype 3 viruses (red lines) than in cases of infection with other 
genotypes (white lines). HCV genotype 3 has a specific effect not observed with other 
genotypes, involving inhibition of the transcription of the phosphatase and tensin homologue 





Fig. 3 Overview of the main results obtained in studies investigating the impact of the HCV 
core protein sequence on hepatic steatosis development. LD, lipid droplets. FAS, fatty acid 
synthetase. HCVcc, HCV in cell culture. 
  
